Pharmaceuticals, Biotechnology and Life Sciences
Company prepares for shipment of first EasyFEN™ system to Africa as part of global deployment strategyMANKATO, Minn., Dec. 30, 2025…
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis…
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with…
TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera…
Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025…
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior,…
WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing…
Five-Year Financing with Favorable Terms that Significantly Reduce Interest RateSTOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.…
GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a…
Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any…